SCHEMBL12725151

SCHEMBL12725151

COC(=O)c1nn(C(=O)OC(C)(C)C)cc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.39
NPSR1 Q6W5P4 1/20 0.35
TP53 P04637 2/20 0.34
F2 P00734 1/20 0.34
ALDH1A1 P00352 5/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 2/20 0.33
HSD17B10 Q99714 2/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
CFTR P13569 1/20 0.33
ROCK2 O75116 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP1A2 P05177 1/20 0.32
NPC1 O15118 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17837216 0.83 ROCK2 (0.34) NR1H2F2ALDH1A1KDM4EMAPT
SCHEMBL12725156 0.79 NR1H2 (0.39) NR1H2NPSR1ALDH1A1LMNAKMT2A
SCHEMBL1559237 0.78 ROCK2 (0.34) NR1H2KDM4EMAPTROCK2SMN1; SMN2
SCHEMBL19208770 0.76 ENPP2 (0.36) NPSR1TP53ALDH1A1LMNAKMT2A
SCHEMBL17966676 0.75 NPSR1 (0.39) NPSR1TP53F2ALDH1A1KMT2A
SCHEMBL28395197 0.73 NPSR1 (0.43) NPSR1TP53F2ALDH1A1KMT2A
SCHEMBL1879910 0.73 CNR2 (0.46) NPSR1TP53ALDH1A1KMT2AKDM4E
SCHEMBL17093908 0.72 F2 (0.31) NR1H2F2KMT2AJAK2JAK1
SCHEMBL31105862 0.72 ROCK2 (0.34) NR1H2F2ROCK2SCD
SCHEMBL13070808 0.71 BCHE (0.35) NR1H2KMT2AKDM4EMAPTROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932257-B2 Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
US-7932257-B2 Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 US disclosed
WO-2007013964-A1 PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2007-02-01 WO disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors AURKA, AURKB, AURKC NR1H2 3239/4885NPSR1 4402/4885TP53 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.